Navigation Links
Phase II trails of new HIV vaccine to be held in South Africa

In a step further to combat the AIDS epidemic, South Africa's first Phase II HIV vaccine trials were launched by charitable group the International AIDS Vaccine Initiative (IAVI) and U.S.-based Targeted Genetics Corporation. //

The trials will test the safety of "tgAAC09" is a preventive HIV vaccine candidate that is based on HIV subtype C, the subtype of the virus most prevalent in southern and eastern Africa, the two groups said in a joint statement on Monday.

Sub-Saharan Africa is the region hardest hit by AIDS, with more than 25 million people estimated to be infected with HIV, the virus that leads to the disease.

South Africa has the highest caseload of HIV in the world, with about one in nine of its 45 million population carrying the virus, while in neighbouring Botswana and Swaziland prevalence is as high as 40 percent.

"We are pleased that South Africa has taken a leading role in the testing of vaccine candidates given the medical and humanitarian promise a preventative vaccine holds," said Eftyhia Vardas, a doctor at the country's Perinatal HIV Research Unit, who will coordinate the trials.

Investigators test the immune response and acquire more data on safety during second phase trials on drugs that have already been proven safe during first phase tests. tgAAC09 is designed to elicit two different types of immune responses, an antibody response and a cell mediated response. The vaccine consists of an artificially made copy of the HIV virus and cannot cause HIV infection or Aids," the IAVI said on Monday.

The vaccine candidate, developed by U.S.-based Targeted Genetics, will be tested on 78 healthy volunteers at three sites in South Africa. The trial is expected to last 18 months.

IAVI, a global non-profit organisation working to accelerate the development of an AIDS vaccine, estimates that around 30 preventative HIV vaccine candidates are in human trials in six continents.


'"/>




Page: 1 2

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Phase 3 trials of two multi-kinase inhibitors against cancer
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented

Post Your Comments:
(Date:11/27/2009)... , SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCal...nounced that Blair Lambert, CFO/COO, will present ...l be held at the May Fair Hotel in London, England...T. ,, To listen to a live broadcast of The Gymb... please log on to www.gymboree.com, click on "Our ...
(Date:11/27/2009)... , NEUILLY-SUR-SEINE, France, Nov. 27 /PRNe...can professional cycling team dedicated to ethical...cling champions, announced today that it will beco...ansitions Optical as a new sponsor of the team. Tr...rer of adaptive eyewear, offering the most advance...
(Date:11/27/2009)... XenaCare Holdings has announ...rthritis Foundation, one of the largest nonprofit ...public health education. , ...naCare Holdings, Inc. (OTCBB: XCHO), a company spe... of consumer healthcare products, has announced to...
(Date:11/27/2009)...ing rates to bring unprecedented medical, economic.... 27 (HealthDay News) -- The number of people with...le over the next 25 years, a new study predicts. ,....1 million people with the disease, up from 23.7 m...treating people with diabetes will triple, the stu...
(Date:11/27/2009)... Voyant Health™ announc...gan) has licensed its TraumaCad Enterprise orthope...orkflow solution. , (PRWE...nced today that Spectrum Health (Grand Rapids, Mic...pedic templating solution and its TraumaCad Extend...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...ards, Find Inspiration in Video Blogs on,Determine...r,couple,s video blogs documenting their efforts t... Pennsylvania Department of Health,s new tobacco,c...to quit smoking together, not just for themselves,...
...eth Campaign to Eliminate Compounded Hormones, WA...mpounding Pharmacists (IACP) today called on the A...AACE) and the North American,Menopause Society (NA...nt. In recent weeks, AACE, NAMS and other supposed...
...dividuals or families may have underlying speech d...ews) -- People with a personal or family history o...rare type of dementia that causes them to lose lan... and progressively impaired, even though the perso...
...ith the recent announcement by,the United States F...ng,safety review of Botox Cosmetic (botulinum toxi...to treat frown lines between the brows. Botox(R),C... In its recent communication, the FDA reports adve...
...Healthcare Services,Inc. (NYSE: AHS ), the nation...oday that Hala Moddelmog, President and Chief Exec...joined the company,s Board of,Directors., "Hala b...ng president and strategic leader of a successful,...
... first PDP to conduct ePrescribing Pilot Study, F...s a bill that would tie physicians, Medicare payme... Health Solutions, Inc. (NYSE: MHS ) today,announ...escriptions. The pilot program will also be used t...
Other Medicine News:Health News:American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals 2Health News:Learning Disabilities May Presage Later Language Problems 2Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 3Health News:Medco Launches Medicare Part D Initiative to Promote ePrescribing 2Health News:Medco Launches Medicare Part D Initiative to Promote ePrescribing 3Health News:Medco Launches Medicare Part D Initiative to Promote ePrescribing 4
(Date:11/25/2009)...lif., Nov. 25 ChemoCentryx, Inc....from the Company,s PROTECT-1 (the Prospective Rand...Trial) of Traficet-EN(TM) (CCX282-B) in patients w...d clinical efficacy with a favorable safety and to...ce of clinical efficacy in the reduction of diseas...
(Date:11/24/2009)...Nov. 24 Endologix, Inc. ...treatments for aortic disorders, announced today t...all proceedings in, the patent infringement lawsui... The motion was filed in the United States Distri... has requested that the stay remain in effect whil...
(Date:11/24/2009)...24 Anadys Pharmaceutical...ill present at the 21st Annual Piper Jaffray Healt...:00 a.m. EST (6:00 a.m. PST). The conference is b...land, Ph.D., President and Chief Executive Officer... its clinical development programs, ANA598 and ANA...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Blood Tests May Spot Colon Cancer 58044 1Blood Tests May Spot Colon Cancer 58044 2Blood Tests May Spot Colon Cancer 58044 3Blood Tests May Spot Colon Cancer 58044 4Prix Galien USA to Launch a Health Care Dialogue Among World Leading Innovators in Science Economics and Biotech 58040 1Prix Galien USA to Launch a Health Care Dialogue Among World Leading Innovators in Science Economics and Biotech 58040 2SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100 25 Yields 14215 1SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100 25 Yields 14215 2
...wing the candidate vaccine induced neutralizing a...ERFIELD, Ill., June 11 Baxter International,Inc. ..., 2008 issue of The,New England Journal of Medicin...avian influenza (H5N1) vaccine, CELVAPAN, met Phas...ty (generating a functional immune,response). This...
...JOLLA, Calif., June 11 Duska Therapeutics,Inc. (O...), announced today,that it has been granted an exc... Johns Hopkins University to develop and commercia...l cardiovascular drugs for the,treatment of heart ...s,expected to enter a Phase II clinical study late...
Other Medicine Technology:The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 2Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 3
Siemens Webcast
Siemens Webcast: Legislative Developments Impacting Cardiology Services Reimbursement
...ny pH catheters are designed for patient comfort a...re number marked at 5cm intervals and line marked ...models are available spanning most clinical needs ...e models with one or two sensors., ,Flexilog sing...
...ny pH catheters are designed for patient comfort a...re number marked at 5cm intervals and line marked ...models are available spanning most clinical needs ...e models with one or two sensors., ,A range of fo...
Medicine Products: